Trial Profile
A Comparison of Effects of Standard Dose vs. Low Dose Advagraf With IL-2 Receptor Antibody Induction, MMF and Steroids, With or Without ACEi/ARB - Based Antihypertensive Therapy on Renal Allograft Histology, Function, and Immune Response
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary) ; Basiliximab; Corticosteroids; Corticosteroids; Irbesartan; Methylprednisolone; Mycophenolate mofetil; Prednisone; Ramipril
- Indications Renal transplant rejection
- Focus Adverse reactions; Registrational
- Sponsors Astellas Pharma
- 23 Dec 2018 Primary endpoint has not been met. (The prevalence of IF/TA (defined as ci+ct2) at Month 24 (in the ACEi/ARB vs OAHT intervention groups).), as reported in ab article published in the American Journal of Transplantation.
- 23 Dec 2018 Primary endpoint has not been met. (The incidence of allograft interstitial fibrosis and tubular atrophy (IF/TA) as assessed at a central pathology lab), as reported in ab article published in the American Journal of Transplantation.
- 23 Dec 2018 Results published in the American Journal of Transplantation